TY - JOUR
T1 - Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies
AU - Di Stasi, Antonio
AU - Jimenez, Antonio M.
AU - Minagawa, Kentaro
AU - Al-Obaidi, Mustafa
AU - Rezvani, Katayoun
N1 - Publisher Copyright:
© 2015 Di Stasi, Jimenez, Minagawa, Al-Obaidi and Rezvani.
PY - 2015
Y1 - 2015
N2 - We performed a systematic review of data from nine clinical trials of WT1 peptide vaccination in patients with myelodysplastic syndromes and/or acute myeloid leukemia (MDS/AML), published between 2004 and 2012. A total of 51 patients were eligible for analysis. Vaccination with WT1 peptides proved safe and feasible in patients with MDS/AML, in studies from different institutions. Additionally, clinical responses and clinical benefit were observed, with some patients achieving and maintaining remission long-term (more than 8 years). A significant correlation between induction of WT1-specific T cells and normalization/reduction of WT1 mRNA levels and progression-free survival was noted in a number of studies. However, larger studies are warranted to confirm these results. Interestingly, the majority of trials reported the presence of WT1-specific T cells with limited or absent functionality prior to vaccination, which increased in frequency and function after vaccination. In conclusion, WT1 peptide vaccination strategies were safe in this heterogeneous group of patient with MDS/AML. Larger and more homogeneous studies or randomized clinical trials are needed to quantify the contribution of WT1 peptide vaccines to clinical responses and long-term survival.
AB - We performed a systematic review of data from nine clinical trials of WT1 peptide vaccination in patients with myelodysplastic syndromes and/or acute myeloid leukemia (MDS/AML), published between 2004 and 2012. A total of 51 patients were eligible for analysis. Vaccination with WT1 peptides proved safe and feasible in patients with MDS/AML, in studies from different institutions. Additionally, clinical responses and clinical benefit were observed, with some patients achieving and maintaining remission long-term (more than 8 years). A significant correlation between induction of WT1-specific T cells and normalization/reduction of WT1 mRNA levels and progression-free survival was noted in a number of studies. However, larger studies are warranted to confirm these results. Interestingly, the majority of trials reported the presence of WT1-specific T cells with limited or absent functionality prior to vaccination, which increased in frequency and function after vaccination. In conclusion, WT1 peptide vaccination strategies were safe in this heterogeneous group of patient with MDS/AML. Larger and more homogeneous studies or randomized clinical trials are needed to quantify the contribution of WT1 peptide vaccines to clinical responses and long-term survival.
UR - http://www.scopus.com/inward/record.url?scp=84926616368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926616368&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2015.00036
DO - 10.3389/fimmu.2015.00036
M3 - Short survey
AN - SCOPUS:84926616368
SN - 1664-3224
VL - 6
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - FEB
M1 - 00036
ER -